|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
EYE » Topics » million in pre-tax charges related to restructurings, transactions, recapitalizations and forfeiture of stock options by senior management; a $5.8 million pre-tax unrealized gain on derivative instruments, and an $11.1 million tax benefit from reversal ofThis excerpt taken from the EYE 8-K filed Feb 20, 2009. million in pre-tax charges related to restructurings, transactions, recapitalizations and forfeiture of stock options by senior management; a $5.8 million pre-tax unrealized gain on derivative instruments, and an $11.1 million tax benefit from reversal of valuation allowances on deferred tax assets.
In 2007, the company reported a GAAP net loss of $192.9 million, or a net loss of $3.22 per share, primarily reflecting the impacts of the 2006 and 2007 eye care recalls. The net loss also reflected acquisition-related charges, an unrealized loss on derivative instruments and a deferred financing cost write-off, which together was estimated to account for approximately $2.26 of the per share loss.
|
| |||||||